More on RLMD

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (6.0 Score)

Upcoming Events

- Earnings (11/5/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Relmada Therapeutics (NQ:RLMD)
Delayed: 4.43 +0.06 (1.37%)
Prev. Close $4.37  
Open$4.35 
52 Wk High$4.10 
52 Wk Low$0.87 
Day High$4.44 
Day Low$4.32 
P/E N/A  
EPS$0.00 
Volume675,556 

Friends, Peers and Foes (?): ABL, ABM, ASTE, BHE, BZH (more...)

Aug 14, 2026 01:18 PM Form SCHEDULE 13G/A RELMADA THERAPEUTICS, Filed by: Squadron Capital Management LLC
Aug 14, 2026 01:00 PM Mizuho sees a chance to buy this biotech stock after recent weakness
Aug 11, 2026 05:10 AM Mizuho Reiterates Outperform Rating on Relmada Therapeutics Inc (RLMD)
Aug 6, 2026 05:05 PM Relmada Therapeutics (RLMD) Tops Q2 EPS by 8c
Aug 6, 2026 04:44 PM Form 8-K RELMADA THERAPEUTICS, For: Aug 06
Aug 6, 2026 04:20 PM Form 10-Q RELMADA THERAPEUTICS, For: Jun 30
Aug 6, 2026 04:05 PM Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Jul 29, 2026 03:22 PM Form SCHEDULE 13G RELMADA THERAPEUTICS, Filed by: BlackRock, Inc.
Jul 28, 2026 08:36 AM Form 8-K RELMADA THERAPEUTICS, For: Jul 28
Jul 28, 2026 08:31 AM Relmada Therapeutics names Bipin Dalmia as chief business officer
View All Articles

Entities mentioned with RLMD

View All Entities